June 8, 2017 08:22 AM EDT
Pharma

Hunt­ing new deals, Eli Lil­ly bud­dies up on di­a­betes R&D with $55M pact

John Carroll

Editor & Founder

New Eli Lil­ly CEO David Ricks has an­oth­er deal to re­port.

Just a few months af­ter com­plet­ing a pact to ac­quire CoLu­cid’s mi­graine drug in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

As­traZeneca de­tails its oral SERD 'switch­ing' reg­i­men as fea­si­bil­i­ty ques­tions re­main

Take­da, Pro­tag­o­nist un­veil ple­nary da­ta for po­ten­tial block­buster rare blood dis­ease drug

As life-sav­ing check­point drugs move to ear­li­er can­cers, re­searchers de­bate how best to use them

Arv­inas, Pfiz­er's PRO­TAC in breast can­cer no bet­ter than oral SERDs

Gilead, Mer­ck re­veal 'prac­tice-chang­ing' da­ta for Trodelvy-Keytru­da com­bo in ag­gres­sive breast can­cer

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times